Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures

BackgroundThe high acute costs of cardiovascular disease and acute cardiovascular events are well established, particularly in terms of direct medical costs. The costs associated with lost work productivity have been described in a broad sense, but little is known about workplace absenteeism or short term disability costs among high cardiovascular risk patients. The objective of this study was to quantify workplace absenteeism (WA) and short-term disability (STD) hours and costs associated with cardiovascular events and related clinical procedures (CVERP) in United States employees with high cardiovascular risk.MethodsMedical, WA and/or STD data from the Truven Health MarketScan® Research Databases were used to select full-time employees aged 18–64 with hyperlipidemia during 2002–2011. Two cohorts (with and without CVERP) were created and screened for medical, drug, WA, and STD eligibility. The CVERP cohort was matched with a non-CVERP cohort using propensity score matching. Work loss hours and indirect costs were calculated for patients with and without CVERP and by CVERP type. Wages were based on the 2013 age-, gender-, and geographic region-adjusted wage rate from the United States Bureau of Labor Statistics.ResultsA total of 5,808 WA-eligible, 21,006 STD-eligible, and 3,362 combined WA and STD eligible patients with CVERP were well matched to patients without CVERP, creating three cohorts of patients with CVERP and three cohorts of patients without CVERP. Demographics were similar across cohorts (mean age 52.2-53.1 years, male 81.3-86.8 %). During the first month of follow-up, patients with CVERP had more WA/STD-related hours lost compared with patients without CVERP (WA-eligible: 23.4 more hours, STD-eligible: 51.7 more hours, WA and STD-eligible: 56.3 more hours) (p < 0.001). Corresponding costs were $683, $895, and $1,119 higher, respectively (p < 0.001). Differences narrowed with longer follow-up. In the first month and year of follow-up, patients with coronary artery bypass graft experienced the highest WA/STD-related hours lost and costs compared with patients with other CVERP.ConclusionsCVERP were associated with substantial work loss and indirect costs. Prevention or reduction of CVERP could result in WA and STD-related cost savings for employers.

[1]  W. Lynch,et al.  Change in Health Risks and Work Productivity Over Time , 2004, Journal of occupational and environmental medicine.

[2]  J. Curtis,et al.  Cost burden of second fracture in the US health system. , 2011, Bone.

[3]  Gary Johns,et al.  Presenteeism in the workplace: A review and research agenda. , 2010 .

[4]  Julie A. Anderson,et al.  Costs of asthma among US working adults. , 2011, The American journal of managed care.

[5]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[6]  A. Bower,et al.  The direct and indirect costs of long bone fractures in a working age US population , 2013, Journal of medical economics.

[7]  J Wasserman,et al.  The relationship between modifiable health risks and health care expenditures. An analysis of the multi-employer HERO health risk and cost database. , 1998, Journal of occupational and environmental medicine.

[8]  S. Serxner,et al.  The Impact of Behavioral Health Risks on Worker Absenteeism , 2001, Journal of occupational and environmental medicine.

[9]  Myde Boles,et al.  The Relationship Between Health Risks and Work Productivity , 2004, Journal of occupational and environmental medicine.

[10]  D. Edington,et al.  Financial Costs Due to Excess Health Risks Among Active Employees of a Utility Company , 2006, Journal of occupational and environmental medicine.

[11]  M. Rayner,et al.  The economic burden of coronary heart disease in the UK , 2002, Heart.

[12]  Ron Z. Goetzel,et al.  Health, Absence, Disability, and Presenteeism Cost Estimates of Certain Physical and Mental Health Conditions Affecting U.S. Employers , 2004, Journal of occupational and environmental medicine.

[13]  K. Ruiz,et al.  Impact of neutropenic complications on short-term disability in patients with cancer receiving chemotherapy , 2009, Journal of medical economics.

[14]  R. Deyo,et al.  ADAPTING A CLINICAL COMORBIDITY USE WITH ICD-g-CM ADMINISTRATIVE INDEX FOR DATABASES , 1992 .

[15]  George A Mensah,et al.  An overview of cardiovascular disease burden in the United States. , 2007, Health affairs.

[16]  C. Lavie,et al.  Impact of worksite wellness intervention on cardiac risk factors and one-year health care costs. , 2009, The American journal of cardiology.

[17]  R. Bitton The economic burden of osteoarthritis. , 2009, The American journal of managed care.

[18]  A. Burdorf,et al.  Productivity loss in the workforce: associations with health, work demands, and individual characteristics. , 2009, American journal of industrial medicine.

[19]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[20]  D. Edington,et al.  Associations between Health Risk Appraisal Scores and Employee Medical Claims Costs in a Manufacturing Company , 1991, American journal of health promotion : AJHP.

[21]  R. Goetzel,et al.  The Relationship between Modifiable Health Risks and Group-Level Health Care Expenditures , 2000, American journal of health promotion : AJHP.

[22]  T. Brennan,et al.  Impact of Medication Adherence on Absenteeism and Short-Term Disability for Five Chronic Diseases , 2012, Journal of occupational and environmental medicine.

[23]  David Thompson,et al.  Cost Estimation of Cardiovascular Disease Events in the US , 2011, PharmacoEconomics.

[24]  M. Jokela,et al.  Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study , 2011, Heart.

[25]  Glenn Pransky,et al.  The Association of Health Risks With On-the-Job Productivity , 2005, Journal of occupational and environmental medicine.

[26]  Ron Goeree,et al.  A review of the cost of cardiovascular disease. , 2009, The Canadian journal of cardiology.

[27]  J. Ruskin,et al.  Economic burden and co‐morbidities of atrial fibrillation in a privately insured population , 2005, Current medical research and opinion.

[28]  David M. Adamson,et al.  HealtH ReseaRcH Data foR tHe Real WoRlD: tHe MaRketscan ® Databases , 2008 .

[29]  R. Straka,et al.  Determining initial and follow-up costs of cardiovascular events in a US managed care population , 2011, BMC cardiovascular disorders.

[30]  Hari Sharma,et al.  Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US , 2012, PharmacoEconomics.

[31]  Harlan M Krumholz,et al.  National Patterns of Risk-Standardized Mortality and Readmission for Acute Myocardial Infarction and Heart Failure: Update on Publicly Reported Outcomes Measures Based on the 2010 Release , 2010, Circulation. Cardiovascular quality and outcomes.

[32]  M Rayner,et al.  Cost of cardiovascular diseases in the United Kingdom , 2006, Heart.

[33]  S. Fienberg,et al.  Current Population Survey , 2012 .

[34]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[35]  P. Austin An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[36]  K. Seung,et al.  Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals , 2009, Circulation.

[37]  Peter C Austin,et al.  The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies , 2010, Statistics in medicine.

[38]  D. Edington,et al.  Measuring the Relationship Between Employees’ Health Risk Factors and Corporate Pharmaceutical Expenditures , 2003, Journal of occupational and environmental medicine.

[39]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[40]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[41]  David M. Smith,et al.  The inpatient experience and predictors of length of stay for patients hospitalized with systolic heart failure: comparison by commercial, Medicaid, and Medicare payer type , 2013, Journal of medical economics.

[42]  G. Pransky,et al.  Caregiving for Ill Dependents and Its Association with Employee Health Risks and Productivity , 2004, Journal of occupational and environmental medicine.

[43]  R. Arena,et al.  Promoting health and wellness in the workplace: a unique opportunity to establish primary and extended secondary cardiovascular risk reduction programs. , 2013, Mayo Clinic proceedings.

[44]  Jessica Grossmeier,et al.  Health Risk Change as a Predictor of Productivity Change , 2015, Journal of occupational and environmental medicine.

[45]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[46]  Jiannong Liu,et al.  Lower Risk of Major Cardiovascular Events Associated with Adherence to Colesevelam HCI , 2013, Pharmacotherapy.

[47]  D. Huse,et al.  A Projection of the Impact of Lipid-Lowering Therapy on High-Risk Employee Disability and Medical Costs , 2006, Journal of occupational and environmental medicine.

[48]  Michael O Harhay,et al.  Impact of minimally invasive surgery on medical spending and employee absenteeism. , 2013, JAMA surgery.

[49]  L. Coupal,et al.  The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? , 2003, Archives of internal medicine.

[50]  E. Finkelstein,et al.  The Economic Burden of Chronic Cardiovascular Disease for Major Insurers , 2007, Health promotion practice.

[51]  S. Girotra,et al.  Acute Coronary Syndrome , 2015, Journal of intensive care medicine.

[52]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[53]  Zhenxiang Zhao,et al.  Economic burden of illness of acute coronary syndromes: medical and productivity costs , 2011, BMC health services research.

[54]  R. Goetzel,et al.  The Direct and Indirect Cost Burden of AcuteCoronary Syndrome , 2011, Journal of Occupational and Environmental Medicine.